Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
BAYER NEW ZEALAND LIMITED,Darolutamide,for patients with high risk non-metastatic-castration resistant prostate cancer (nmCRPC).,Darolutamide (NUBEQA),Options for investment,Community,
